Literature DB >> 16222042

Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair.

Theodore J Standiford1, Venkateshwar G Keshamouni, Raju C Reddy.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily that regulate the expression of genes involved in a variety of biological processes, including lipid metabolism and insulin sensitivity. Members of the PPAR family-in particular, PPAR-gamma-have more recently been shown to broadly regulate inflammatory and reparative responses. PPAR-gamma is expressed in both alveolar macrophages and neutrophils, and the ligand-dependent activation of this receptor results in suppression of leukocyte effector responses, including cytokine production, the elaboration of reactive oxygen and nitrogen species, and migratory responses. In addition to antiinflammatory effects, PPAR-gamma regulates diverse processes in lung stromal/parenchymal cells, including cell growth, differentiation, and apoptosis. Studies examining in vivo effects of PPAR-gamma have produced complex and at times conflicting results. However, evidence to date generally suggests that PPAR-gamma functions to dampen inflammation and injury in various animal models of acute lung injury. PPAR-gamma may also play an important role in other inflammatory/immune lung diseases, including ischemia-reperfusion injury, allergic airway inflammation, and cancer. The role of PPAR-gamma in human lung diseases, including acute lung injury, requires further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222042     DOI: 10.1513/pats.200501-010AC

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  61 in total

1.  Postnatal rosiglitazone administration to neonatal rat pups does not alter the young adult metabolic phenotype.

Authors:  Nghia C Truong; Afshan Abbasi; Reiko Sakurai; W N Paul Lee; John S Torday; Virender K Rehan
Journal:  Neonatology       Date:  2011-11-10       Impact factor: 4.035

Review 2.  Regulators of endothelial and epithelial barrier integrity and function in acute lung injury.

Authors:  Rudolf Lucas; Alexander D Verin; Stephen M Black; John D Catravas
Journal:  Biochem Pharmacol       Date:  2009-02-03       Impact factor: 5.858

Review 3.  MUC1 mucin: a peacemaker in the lung.

Authors:  K Chul Kim; Erik P Lillehoj
Journal:  Am J Respir Cell Mol Biol       Date:  2008-07-10       Impact factor: 6.914

4.  Phagocytic clearance of apoptotic cells: role in lung disease.

Authors:  Jeong H Yun; Peter M Henson; Rubin M Tuder
Journal:  Expert Rev Respir Med       Date:  2008-12       Impact factor: 3.772

5.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

6.  Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock.

Authors:  Ranjit S Chima; Paul W Hake; Giovanna Piraino; Prajakta Mangeshkar; Alvin Denenberg; Basilia Zingarelli
Journal:  Crit Care Med       Date:  2008-10       Impact factor: 7.598

7.  Regulation of the mucosal phenotype in dendritic cells by PPARγ: role of tissue microenvironment.

Authors:  Halide Tuna; Rita G Avdiushko; Vishal J Sindhava; Leia Wedlund; Charlotte S Kaetzel; Alan M Kaplan; Subbarao Bondada; Donald A Cohen
Journal:  J Leukoc Biol       Date:  2013-12-02       Impact factor: 4.962

8.  α-Linoleic acid enhances the capacity of α-1 antitrypsin to inhibit lipopolysaccharide induced IL-1β in human blood neutrophils.

Authors:  Nupur Aggarwal; Elena Korenbaum; Ravi Mahadeva; Stephan Immenschuh; Veronika Grau; Charles A Dinarello; Tobias Welte; Sabina Janciauskiene
Journal:  Mol Med       Date:  2016-10-04       Impact factor: 6.354

9.  Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1.

Authors:  Alexander Hoetzel; Tamas Dolinay; Simone Vallbracht; Yingze Zhang; Hong Pyo Kim; Emeka Ifedigbo; Sean Alber; A Murat Kaynar; Rene Schmidt; Stefan W Ryter; Augustine M K Choi
Journal:  Am J Respir Crit Care Med       Date:  2008-03-20       Impact factor: 21.405

10.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.